Archive · 25 Jul 2025
Syngene Q1 Boosted by Research Services and Manufacturing
Imagine a company called Syngene that helps make medicines.
They had a great start this year, making more money than before!
They're growing because they're good at doing research and making things for their clients.
They expect to keep growing, but at a slower pace because they are building new facilities, and that costs money.
They are also making more medicines, and they see a big opportunity to get even bigger in the future.
Syngene International reported an 11% revenue growth and a 61% jump in PAT to ₹87 crore in Q1 FY25.
Research services drove the growth, with strong pilot project conversions and direct client engagements.
The company expects PAT growth to moderate in upcoming quarters due to depreciation from new facilities.
Manufacturing, particularly from Bengaluru and Bayview, is expected to contribute more in the coming quarters.
Syngene sees significant headroom in the growing $250 billion global CDMO market.
- Who
- Syngene International and its MD & CEO Peter Bains.
- What
- Syngene International's Q1 FY25 performance and future outlook.
- When
- Q1 FY25.
- Where
- Bengaluru, US (Bayview facility in Maryland), and globally.
- Why
- Driven by strong demand in research services and the gradual ramp-up of manufacturing capacities, with expectations for continued growth in the CDMO market.
Optimistic Outlook
Moderated Growth Expectations
Growth Trajectory
Optimistic Outlook
Syngene anticipates continued growth driven by strong research services and manufacturing expansion.
Moderated Growth Expectations
The growth in PAT is expected to moderate in the coming quarters.
- Revenue Growth (Q1 FY25)
- 11%
- PAT Growth (Q1 FY25)
- 61%
- PAT (Q1 FY25)
- ₹87 crore
- EBITDA Margin
- 25%
- Global CDMO Market Size
- $250 billion
- CDMO Market Growth
- 8–9% annually